How Greenleaf was paid
$5.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Peter GreenleafFormer President, Chief Executive Officer and Director | $822,877 | $1,965,321 | $2,193,189 | $864,021 | $13,182 | $5,858,590 |
| Joseph MillerFormer Chief Financial Officer | $526,988 | $550,649 | $614,491 | $395,241 | $15,378 | $2,102,747 |
| Matthew DonleyFormer Chief Operating Officer | $567,636 | $559,600 | $624,484 | $425,727 | $59,641 | $2,237,088 |
| Gregory Keenan, M.D.Former Chief Medical Officer | $516,233 | $423,060 | $472,108 | $348,458 | $14,382 | $1,774,241 |
| Stephen RobertsonChief Legal Officer, Corporate Secretary and Chief Compliance Officer | $481,900 | $568,557 | $634,473 | $361,425 | $80,155 | $2,126,510 |
What changed and why
- $5.9MPeter Greenleaf total compensation decreased to $5,858,590 in fiscal year 2025.
- Stock options and performance stock units were granted as annual equity incentives.
- Peter Greenleaf and other executive officers ceased to serve as officers in March 2026.
- Kevin Tang was appointed Chief Executive Officer in 2026 and elected to receive no compensation.
- Performance stock units vest in 4 tranches tied to company share price increases.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.